Considering the therapeutic use of monoclonal antibodies (mAbs) against PD-L1 in malignant tumor treatment such as atezolizumab, avelumab, and durvalumab, it is already known that secreted PD-L1 can effectively block immune effector cells in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.